Last Updated on October 2, 2024 by The Health Master
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organization (CDSCO) has granted approval to the drug maker Ajanta Pharma to conduct bioequivalence (BE) study of Tadalafil Oral Jelly 20 mg (Orange Flavour), indicated for the treatment of erectile dysfunction in adult men.
However, the approval is subject to condition that physician opinion should be taken before enrolment the subjects in the study.
This came after the firm presented its proposal of manufacture and marketing permission for Tadalafil Oral Jelly 20 mg (Orange Flavour), indicated for the treatment of erectile dysfunction in adult men, along with bioequivalence (BE) study protocol before the committee.
Tadalafil is in a class of medications called phosphodiesterase (PDE) inhibitors.
It is an inhibitor that produces several downstream effects with the most common therapeutic effect being smooth muscle relaxation.
Tadalafil is used to treat male sexual function problems (impotence or erectile dysfunction-ED).
In combination with sexual stimulation, tadalafil works by increasing blood flow to the penis to help a man get and keep an erection.
Tadalafil is also used to treat the symptoms of an enlarged prostate (benign prostatic hyperplasia-BPH).
It helps to relieve symptoms of BPH such as difficulty in beginning the flow of urine, weak stream, and the need to urinate frequently or urgently (including during the middle of the night).
At the recent SEC meeting for Reproductive & Urology held on December 23, 2022, the expert panel reviewed the proposal of manufacture and marketing permission for Tadalafil Oral Jelly 20 mg (Orange Flavour) for the indication “It is indicated for the treatment of erectile dysfunction in adult men” along with BE protocol before the committee.
After detailed deliberation, the committee recommended the grant of permission to conduct BE study of Tadalafil Oral Jelly 20 mg (Orange Flavour) as per the protocol presented subject to the condition that the physician’s opinion should be taken before enrolment of the subjects in the study.
Accordingly, the committee recommended that the firm should submit BE study report for further review by the committee and consideration of clinical trials of the applied drug product
CDSCO Panel gives nod Clinical Trial for this Anticancer Drug
CDSCO Panel gives nod for FDC Tamsulosin + Solifenacin
CDSCO panel gives nod for Esomeprazole Dual Release Gastro resistant Tablets
CDSCO gives approval for this Anti-diabetic drug
CDSCO gives nod to Dapagliflozin Tablets
CDSCO approves 4 more Medical Device Testing Labs (MDTL)
List of approved New Drugs Updated
No need to recall, re-label the drug for price revision if…….:NPPA
ICMR releases Antimicrobial guidelines 2022
CDSCO Panel gives nod Clinical Trial for this Anticancer Drug
USFDA gives final approval for this Insomnia drug
Antibiotics need to be developed urgently for newborns: Experts
Drug recall: 4 lots of Quinapril Tablets recalled due to this reason
IPC launches 10 new impurities standards
Registration for sale of Medical Devices: Procedure and conditions
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
